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ORIGINAL RESEARCH
Pharmacotherapy in the Management of 
Anxiety and Pain During Acute Coronary 
Syndromes and the Risk of Developing 
Symptoms of Posttraumatic Stress Disorder
Roland von Känel , MD; Jean-Paul Schmid, MD; Rebecca E. Meister-Langraf, PhD; Jürgen Barth, PhD; 
Hansjörg Znoj, PhD; Ulrich Schnyder, MD; Mary Princip, PhD*; Aju P. Pazhenkottil, MD*
BACKGROUND: Benzodiazepines and morphine are given during acute coronary syndromes (ACSs) to alleviate anxiety and pain, 
and β-blockers may also reduce pain. ACS may induce posttraumatic stress disorder (PTSD) symptoms (PTSS). When taken 
during trauma other than ACS, benzodiazepines increase the risk of PTSS, but it is unknown if benzodiazepines increase the 
risk of PTSS in ACS. We examined the effects of drug exposure during ACS on the development of PTSS.
METHODS AND RESULTS: Study participants were 154 patients with a verified ACS. Baseline demographics, clinical variables, 
and psychological measures were obtained through a medical history, through a psychometric assessment, and from patient 
records, and used as covariates in linear regression analysis. Three months after ACS, the severity of PTSS was assessed with 
the Clinician-Administered PTSD Scale. During ACS, 37.7% of patients were exposed to benzodiazepines, whereas 72.1% 
were exposed to morphine and 88.3% were exposed to β-blockers, but only 7.1% were exposed to antidepressants. Eighteen 
(11.7%) patients developed clinical PTSD. Adjusting for all covariates, benzodiazepine use was significantly associated with 
the Clinician-Administered PTSD Scale total severity score (unstandardized coefficient B [SE], 0.589 [0.274]; partial r=0.18; 
P=0.032) and the reexperiencing subscore (B [SE], 0.433 [0.217]; partial r=0.17; P=0.047). Patients exposed to benzodiaz-
epines had an almost 4-fold increased relative risk of developing clinical PTSD, adjusting for acute stress disorder symptoms 
(odds ratio, 3.75; 95% CI, 1.31–10.77). Morphine, β-blockers, and antidepressants showed no predictive value.
CONCLUSIONS: Notwithstanding short-term antianxiety effects during ACS, benzodiazepine use might increase the risk of ACS-
induced PTSS with clinical significance, thereby compromising patients’ quality of life and prognosis.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT01781247.
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C
oronary care unit staff has long been aware 
that the average patient with an acute coronary 
syndrome (ACS) is anxious at the time of hos-
pital admission,1 with the mean state anxiety level in 
patients doubling that of a normal reference group.2 
Within 48 hours of ACS onset, almost 50% of patients 
report anxiety,3 and about half of these have high levels 
of anxiety.4,5 Guidelines of the European Society of 
Cardiology recommend the use of a mild tranquillizer, 
usually a benzodiazepine, for the treatment of anxious 
patients presenting with ST-segment–elevation myo-
cardial infarction (STEMI).6
Two major reasons for acute anxiety during ACS 
are fear of dying and pain.1 Clinically significant fear of 
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dying and acute distress occur in 2 of 3 patients during 
ACS and are strongly correlated with chest pain.7 
Intravenous opioids are usually necessary for effective 
pain relief,6 but the combination with benzodiazepine 
can reduce the use of morphine and its adverse ef-
fects.8,9 Benzodiazepines rapidly relieve the anxiety 
triggered by ischemic chest pain, thus counteracting 
a vicious cycle of pain, anxiety, and distress, associ-
ated with sympathetic activation causing increased 
workload of the heart.10 Intravenous β-blockers, ap-
plied to reduce malignant ventricular arrhythmias in 
patients with ACS,6 have also marked pain-relieving 
effects.11 Patients often receive a combination of ben-
zodiazepine, morphine, and β-blockers, although it is 
unknown how these drugs are to be combined to man-
age anxiety and pain during ACS most effectively.12
Induced by the traumatic experience of ACS as 
a life-threatening disease,13 patients develop post-
traumatic stress disorder (PTSD) in 4% and clinically 
significant PTSD symptoms (PTSS) in 12% after 1 to 
12 months.14 Typical PTSS may include reexperiencing 
aspects of ACS in thoughts or dreams, avoidance of 
activities that remind of ACS, and hyperarousal symp-
toms.15 Notwithstanding their short-term antianxiety 
effects, benzodiazepines could be a risk factor for the 
development of ACS-induced PTSS, seen in critical 
illness survivors exposed to benzodiazepines in the 
intensive care unit.16 Moreover, benzodiazepines in-
crease the risk of developing PTSD at least 2-fold in 
patients who experience trauma, because benzodiaze-
pines could interfere with the acute physiological stress 
response and memory-related processes necessary to 
cope with PTSS.17 On the other hand, a decrease in 
both pain and fear conditioning could explain less se-
vere PTSS at follow-up in civilian and military patients 
who received morphine within hours of trauma.18,19 Pain 
and fear of dying during ACS are risk factors for the de-
velopment of PTSS,20,21 but effects of morphine use on 
ACS-induced PTSS have not yet been investigated.13 
There is currently no meta-analytic evidence that an-
tidepressants or the β-blocker propranolol prevents 
the development of PTSS after a traumatic event.22,23 
However, one previous study observed lowered PTSS 
at 1  month in patients with β-blockers during emer-
gency department evaluation for ACS.24
On the basis of the current evidence, the primary 
aim of our observational study was to test the hypoth-
esis that exposure to benzodiazepines during ACS is 
associated with increased severity of PTSS 3 months 
later. Our secondary aim was to explore effects of mor-
phine, β-blocker, and antidepressant exposure during 
ACS on ACS-induced PTSS at 3 months.
METHODS
Study Participants and Design
The data that support the findings of this study are 
available from the corresponding author on reason-
able request. The participants of this study were en-
rolled in the MI-SPRINT (Myocardial Infarction–Stress 
Prevention Intervention) randomized controlled trial 
aimed at preventing the development of ACS-induced 
PTSS through an early behavioral intervention.25 We 
did not include the intervention in the current analysis 
CLINICAL PERSPECTIVE
What Is New?
• Patients receiving benzodiazepines in the set-
ting of an acute myocardial infarction had more 
severe infarction-induced posttraumatic stress 
symptoms of clinical significance at 3  months 
than patients not prescribed benzodiazepines.
• For individual posttraumatic stress symptom 
clusters, an association with benzodiazepine 
use was particularly observed for reexperienc-
ing aspects of myocardial infarction, for instance 
in thoughts or dreams.
• The effect was independent of demographic 
factors, clinical and psychosocial variables, and 
concomitant exposure to morphine, β-blockers, 
and antidepressants.
What Are the Clinical Implications?
• Although benzodiazepines provide rapid relief 
from anxiety during myocardial infarction, they 
could contribute to posttraumatic stress in the 
longer-term.
• In the setting of an acute myocardial infarction, 
clinicians should prescribe benzodiazepines 
only with a clear indication, knowing that infarc-
tion-induced posttraumatic stress is associated 
with impaired quality of life and prognosis.
• As our findings are not from a randomized con-
trolled trial, it is possible that patient character-
istics leading to posttraumatic stress and the 
prescription of benzodiazepines were similar.
Nonstandard Abbreviations and Acronyms
ASD acute stress disorder
CAPS Clinician-Administered Posttraumatic 
Stress Disorder Scale
GRACE Global Registry of Acute Coronary 
Events
MI-SPRINT Myocardial Infarction–Stress  
Prevention Intervention
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because it showed no effect on interviewer-rated 
PTSS at 3-month follow up, the primary end point of 
the present study, which was assessed in 154 pa-
tients.26 We included patients aged ≥18  years with 
verified STEMI or non–ST-segment–elevation myo-
cardial infarction (MI), stable circulation, and high peri-
traumatic distress, defined by numeric rating scores 
(range, 0–10) of ≥5 for pain plus ≥5 for fear of dying 
and/or helplessness during ACS.27 We excluded pa-
tients with emergency coronary artery bypass graft-
ing, diseases likely to cause death within 1 year, limited 
orientation, cognitive impairment, current severe de-
pression, according to the cardiologist’s medical his-
tory, suicidal ideations in the previous 2 weeks, and 
insufficient German skills; or when they participated 
in another randomized controlled trial. The local eth-
ics committee approved the trial protocol, which was 
registered under Clini calTr ials.gov (NCT01781247). All 
patients provided written informed consent.
Baseline Measures
Baseline measures were obtained in the coronary 
care unit through a structured medical history, through 
psychometric assessment, and from patient records, 
including information on drugs to which patients were 
exposed during ACS. For benzodiazepines, opioids, 
and β-blockers, “drug exposure” referred to any 
use of these drugs during the short-term treatment 
phase of ACS. For antidepressants, “drug exposure” 
referred to the current use of antidepressants at the 
time of ACS. As a measure of socioeconomic sta-
tus, we categorized educational level as high (univer-
sity graduation, including applied sciences; or high 
school graduation/matura), medium (apprenticeship 
or vocational school), or low (lower than apprentice-
ship or vocational school).28 We used the GRACE 
(Global Registry of Acute Coronary Events) score to 
estimate the cumulative mortality/recurrent ACS risk 
in the following 6 months.29 The Charlson comorbid-
ity index was used as an estimate of low, medium, or 
high 10-year mortality risk.30 Self-rated health with 
reference to the time before ACS was assessed with 
the EuroQol Visual Analogue Scale (https://euroq 
ol.org/euroq ol/), ranging from 0 ("worst imaginable 
health state") to 100 ("best imaginable health state").31 
For information on lifetime depression, patients were 
asked the question, “Have you ever had a depres-
sion in your life? (yes/no).” We used the 19-item 
self-rating Acute Stress Disorder Scale to measure 
acute stress disorder (ASD) symptoms of dissocia-
tion, reexperiencing, avoidance, and arousal, which 
had occurred “since the heart attack.”32 Each item 
is rated on a 5-point Likert scale (0 indicates “not at 
all”; and 4, “extremely”; total severity score, 0–76). In 
patients who completed all items, the Cronbach α 
for the scale was 0.83. We measured negative mood 
with the Global Mood Scale,33 asking participants to 
rate the extent to which they felt each of 10 mood 
states “at the moment” on a 5-point Likert Scale (0 
indicates “not at all”; and 4, “extremely”; total severity 
scale, 0–40). Typical items are “fatigued,” “insecure,” 
and “helpless.” In patients who completed all items, 
the Cronbach α for the scale was 0.85.
Assessment and Classification of PTSS
Three months after ACS, we assessed ACS-induced 
PTSS with the Clinician-Administered PTSD Scale 
(CAPS) on the basis of Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV ), 
criteria.34 Trained interviewers, blinded to the interven-
tion assignment, rated the frequency and intensity 
of each of the 17 PTSS, referring to the prior month 
between 0 (“never”) and 4 (“almost always”); the total 
PTSS severity score is 0 to 136. As an indication of 
the clinical relevance of PTSS, we additionally classi-
fied patients as “full PTSD,” “subsyndromal PTSD,” or 
“non-PTSD” on the basis of whether they met criteria 
for the presence or absence of symptom clusters.35 
One of 5 symptoms is required for the reexperiencing 
cluster, 3 of 7 symptoms are required for the avoid-
ance/numbing cluster, and 2 of 5 symptoms are re-
quired for the hyperarousal cluster. Patients who met 
criteria for all 3 symptom clusters were diagnosed with 
full PTSD. Patients who met criteria for the reexperi-
encing cluster and either the avoidance/numbing or 
the hyperarousal cluster were diagnosed with subsyn-
dromal PTSD. Patients who met full or subsyndromal 
criteria for PTSD were lumped together and defined as 
patients with “clinical PTSD.” Patients who met criteria 
for either one or no symptom cluster were non-PTSD 
cases. The Cronbach α was 0.79 for the CAPS total 
scale, 0.68 for the reexperiencing scale, 0.66 for the 
avoidance/numbing scale, and 0.44 for the hypera-
rousal scale, indicating moderate-to-good internal 
consistency, except for the hyperarousal scale.
Statistical Analysis
Data were analyzed using SPSS 26.0 for Windows 
(SPSS Inc, Chicago, IL) with 2-tailed significance 
of P<0.05. We used multiple imputation to replace 
missing values, applying the default method “auto-
matic.” This imputation method scans the data to de-
termine the best imputation method (fully conditional 
specification or monotone). The following variables 
were used for the imputation model: STEMI, age, 
sex, education, GRACE score, Charlson comorbid-
ity index, self-rated health, depression history, pain 
during MI, fear of dying during MI, ASD symptoms, 
negative mood, all drugs, and all CAPS scores. Five 
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missing values across all variables in the analysis 
was only 3.6% (111 of totally 2969 values missing). 
Specifically, missing values were n=1 for index MI, 
education, and antidepressants; n=3 for lifetime de-
pression history; n=4 for β-blockers; n=5 for benzo-
diazepine and morphine use; n=12 for GRACE score; 
n=25 for ASD Scale score; n=26 for self-rated health; 
and n=28 for negative mood. The Little Missing 
Completely at Random test indicated that quanti-
tative variables were completely missing at random 
(P=0.39). Nonnormal variables were not transformed 
before the imputation. However, after imputation, 
for further analyses, CAPS, GRACE, and ASD Scale 
scores were square root transformed to approximate 
a more normal distribution. There were no significant 
differences in CAPS scores and the proportion of 
benzodiazepine, morphine, β-blocker, and antide-
pressant use between participants with (n=114) and 
those without (n=40) complete data (all P>0.27).
We used independent-sample t-test or χ2 test to de-
termine group differences in parametric and nonpara-
metric variables, respectively, and the Kendall τ-b to 
estimate the correlation between drug exposure and 
patient characteristics. We performed univariable and 
multivariable linear regression analyses to determine 
associations of drug exposure with the CAPS total se-
verity score (primary outcome) and the scores of the 
3 PTSS clusters (secondary outcomes). For the mul-
tivariable analyses, covariates were selected on the 
basis of the literature on risk factors for cardiac dis-
ease–induced PTSS and associations of β-blocker 
or benzodiazepine exposure with the development of 
PTSS in trauma survivors.13,24,36 To avoid overfitting, 
we limited the number of predictors to 15 (11 covari-
ates and 4 drugs). We considered demographics (sex, 
age, and education), clinical variables (GRACE score, 
Charlson comorbidity index, and self-rated health), and 
psychological measures (pain and fear of dying during 
ACS, depression history, ASD symptoms, and nega-
tive mood). For a complementary analysis, we used 
logistic regression to estimate the relative risk of de-
veloping clinical PTSD with drug exposure, adjusting 
for covariates, which were significant and independent 
predictors of the CAPS total score in the linear regres-
sion model. Regression output revealed no influential 




Three months after ACS, 1 patient was diagnosed 
with full PTSD and 17 patients were diagnosed 
with subsyndromal PTSD, bringing the total num-
ber of patients diagnosed with clinical PTSD to 18, 
a prevalence of 11.7%. Table  1 shows the baseline 
characteristics and CAPS scores at 3  months of 
the 154 study participants as a whole group and 
in a group comparison between patients with ver-
sus without clinical PTSD. Most of the study partici-
pants were men, were well educated, and showed 
rather low medical comorbidity. The vast majority 
were treated in the coronary care unit with opioids 
(morphine in all cases) and β-blockers (metoprolol in 
≈90% of cases). Slightly more than a third received 
benzodiazepines (lorazepam in ≈80% of cases). 
Three patients reported current use of benzodiaz-
epines before the ACS, 1 in the group with clinical 
PTSD and 2 in the group with no PTSD; all 3 also 
received a benzodiazepine during ACS. A total of 45 
(29.2%) patients reported having had depression in 
the past, and only 11 (7.1%) patients reported current 
use of antidepressants. Compared with those with-
out clinical PTSD, patients with clinical PTSD were 
significantly younger, were more often diagnosed 
with STEMI than non–ST-segment–elevation MI, and 
had more severe negative mood and, as expected, 
more severe PTSS. Patients with clinical PTSD were 
also more frequently exposed to benzodiazepines, 
although not morphine, β-blockers, or antidepres-
sants, than those without clinical PTSD. The study 
sample characteristics stratified by benzodiazepine 
use are shown in Table 2.
Associations Between Drug Exposure and 
Baseline Characteristics of Patients
There were several zero-order correlations between 
drug exposure at admission and patients’ baseline 
characteristics. The use of benzodiazepine was asso-
ciated with increased fear of dying (r=0.16; P=0.048) 
and increased negative mood (r=0.24; P=0.002). 
Morphine administration was associated with STEMI 
(r=0.18; P=0.025) and increased fear of dying (r=0.19; 
P=0.021). Administration of β-blockers was associated 
with STEMI (r=0.39; P<0.001) and a higher Charlson 
comorbidity index (r=0.17; P=0.043). Exposure to an-
tidepressants was associated with lower self-rated 
health (r=−0.22; P=0.009), depression history (r=0.16; 
P=0.046), and increased negative mood (r=0.18; 
P=0.042).
Association Between Drug Exposure and 
PTSS After 3 Months
Total PTSS Severity
The regressions of the CAPS total severity score on 
drug use at admission, subsequently adjusted for 
blocks of covariates, are summarized in Table 3. The 
use of benzodiazepine was significantly associated 
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correlation coefficients r for the association between 
benzodiazepine use and the CAPS total score ranged 
between 0.18 (fully covariate-adjusted model 5) and 
0.25 (model 4, adjusted for the other drugs and demo-
graphic and clinical variables), suggesting small, but 
clinically significant, effects. The results for the CAPS 
total severity score did not change when the 3 par-
ticipants who had received a benzodiazepine before 
ACS were excluded from the analysis (fully covariate-
adjusted model 5: B [SE], 0.632 [0.276]; partial r=0.20; 
P=0.022). In contrast to benzodiazepine exposure, 
exposure to morphine, β-blockers, or antidepressants 
during MI showed no significant association with the 
CAPS total score at 3 months in any model.
Individual PTSS Clusters
In the univariable model, benzodiazepine use was 
significantly associated with both CAPS reexperienc-
ing (B [SE], 0.547 [0.204]; partial r=0.22; P=0.008) 
and avoidance/numbing (B [SE], 0.512 [0.202]; par-
tial r=0.20; P=0.011) scores, but not hyperarousal 
scores (P=0.21) after 3 months. Benzodiazepine use 
remained significantly associated with reexperienc-
ing (B [SE], 0.433 [0.217]; partial r=0.17; P=0.047) 
but not avoidance/numbing (P=0.098) scores, after 
adjusting for exposure to morphine, β-blockers, and 
antidepressants, age, sex, education, GRACE score, 
Charlson comorbidity index, self-rated health, de-
pression history, pain and fear of dying during MI, 
ASD symptoms, and negative mood. The result for 
reexperiencing symptoms was maintained in the fully 
covariate-adjusted model, when the 3 participants 
who had received a benzodiazepine before ACS were 
excluded from the analysis (B [SE], 0.489 [0.216]; par-
tial r=0.20; P=0.024). There were no significant as-
sociations of morphine, β-blocker, or antidepressant 
exposure during MI with any of the 3 CAPS symptom 
clusters at 3 months, both in univariable and fully ad-
justed multivariable analyses (statistics not shown).
Associations Between Covariates and 
PTSS After 3 Months
In the univariable analysis, shown in Table  2, there 
were several baseline demographic factors, clinical 
Table 1. Characteristics of All Study Participants and Between Groups With and Without Clinical PTSD
Variable All (n=154) Clinical PTSD (n=18) No PTSD (n=136) P Value
Age, mean (SD), y 58.7 (10.9) 53.8 (9.5) 59.4 (10.9) 0.039
Male sex, n (%) 130 (84.4) 16 (88.9) 114 (87.7) 0.741
Educational level, n (%)
High/medium/low 29 (18.8)/114 (74.0)/11 (7.2) 0 (0)/17 (94.4)/1 (5.6) 29 (21.3)/97 (71.3)/10 (7.4) 0.078
ST-segment–elevation MI, n (%) 110 (71.4) 17 (94.4) 93 (68.4) 0.022
GRACE score, median (IQR) 102.5 (84.7–118.4) 95.7 (84.2–121.3) 102.7 (84.7–118.0) 0.884
Charlson comorbidity index, n (%)
Low/medium/high 88 (57.2)/39 (25.3)/27 (17.5) 12 (66.7)/4 (22.2)/2 (11.1) 76 (55.9)/35 (25.7)/25 (18.4) 0.644
Self-rated health, mean (SD) 73.5 (17.4) 68.6 (24.7) 74.1 (18.5) 0.352
Depression history (yes), n (%) 45 (29.2) 8 (44.4) 37 (27.2) 0.135
Pain score, mean (SD) 7.9 (1.6) 7.8 (1.7) 7.9 (1.6) 0.553
Fear of dying score, mean (SD) 5.1 (2.9) 6.2 (2.8) 4.9 (2.9) 0.072
ASD symptoms, median (IQR) 16.2 (9.2–23.0) 17.8 (11.0–27.0) 15.3 (9.0–23.0) 0.388
Negative mood, mean (SD) 14.2 (6.8) 17.4 (4.5) 13.8 (6.9) 0.012
Benzodiazepine, n (%) 58 (37.7) 12 (66.7) 46 (33.8) 0.007
Morphine, n (%) 111 (72.1) 13 (72.2) 98 (72.1) 0.936
β-Blocker, n (%) 136 (88.3) 18 (100) 118 (86.8) 0.168
Antidepressant, n (%) 11 (7.1) 3 (16.7) 8 (5.9) 0.198
CAPS scores, median (IQR)
Total symptom severity 8 (3.0–15.0) 27.5 (23.0–39.8) 6.5 (2.0–11.8) <0.001
Reexperiencing symptoms 2 (0–3.3) 11.0 (9.0–13.0) 0 (0–2.0) <0.001
Avoidance/numbing 
symptoms
2 (0–4.0) 7.5 (2.0–13.5) 1.5 (0–3.0) <0.001
Hyperarousal symptoms 4 (2.0–7.3) 12.0 (9.3–16.0) 4.0 (2.0–6.0) <0.001
The category “Clinical PTSD” includes 1 patient with full PTSD and 17 patients with subsyndromal PTSD. ASD indicates acute stress disorder; CAPS, 
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variables, and psychological measures, which were 
significantly associated with the CAPS total se-
verity score after 3  months. Younger patients and 
those with lower self-rated health, a history of de-
pression, greater fear of dying during MI, more se-
vere ASD symptoms, and negative mood showed 
a higher CAPS total score at 3  months. However, 
in the fully adjusted model 5, only ASD symptoms 
emerged as a significant and independent predictor 
of the CAPS total score. Moreover, adjusting for all 
covariates, there were independent associations of 
ASD symptoms with CAPS reexperiencing (B [SE], 
0.186 [0.078]; P=0.017), avoidance/numbing (B [SE], 
0.196 [0.082]; P=0.017), and hyperarousal (B [SE], 
0.210 [0.078]; P=0.007) scores, and of higher educa-
tion with lower reexperiencing scores (B [SE], −0.629 
[0.191]; P=0.001).
Association Between Drug Exposure and 
Clinical PTSD
As all participants with clinical PTSD had received 
β-blockers, odds ratios (ORs) could only be calcu-
lated for benzodiazepine, morphine, and antidepres-
sant exposure. Patients with benzodiazepine use had 
an almost 4-fold increased risk of developing clinical 
PTSD relative to patients who did not receive a ben-
zodiazepine (OR, 3.89; 95% CI, 1.37–11.04). This re-
sult changed little with additional adjustment for ASD 
symptoms (OR, 3.75; 95% CI, 1.31–10.77) or exposure 
to morphine and antidepressants (OR, 4.31; 95% CI, 
1.46–12.74). In contrast, exposure to morphine (OR, 
1.02; 95% CI, 0.34–3.09) or antidepressants (OR, 3.39; 
95% CI, 0.79–14.43) was not significantly associated 
with an increased risk of developing clinical PTSD; 
these results did not change with additional adjust-
ment for ASD symptoms. The detailed logistic linear 
regression models for these analyses are presented in 
Table S1.
DISCUSSION
As a novelty, the main finding of our study was that pa-
tients who received a benzodiazepine within hours of 
acute MI had more severe PTSS 3 months later com-
pared with patients not exposed to a benzodiazepine. 
This association was robust with adjustment for the 
effects of exposure to morphine and β-blockers, cur-
rent use of antidepressants, and a range of previously 
Table 2. Characteristics of All Study Participants, Stratified by Benzodiazepine Use
Variable Benzodiazepine Use (n=58) No Benzodiazepines (n=96)
Age, mean (SD), y 58.3 (11.0) 58.9 (11.8)
Male sex, n (%) 51 (82.3) 79 (87.9)
Educational level, n (%)
High/medium/low 9 (15.5)/48 (82.8)/1 (1.7) 20 (20.8)/66 (68.8)/10 (10.4)
ST-segment–elevation MI, n (%) 47 (81.0) 64 (66.7)
GRACE score, median (IQR) 105.2 (86.8–121.5) 101.5 (84.0–114.2)
Charlson index, n (%)
Low/medium/high 33 (56.9)/17 (29.3)/8 (13.8) 55 (57.3)/22 (22.9)/19 (19.8)
Self-rated health, mean (SD) 76.1 (17.8) 71.9 (20.0)
Depression history (yes), n (%) 13 (22.4) 32 (33.3)
Pain score, mean (SD) 8.0 (1.8) 7.8 (1.5)
Fear of dying score, mean (SD) 5.7 (3.2) 4.7 (2.7)
ASD symptoms, median (IQR) 20.4 (11.9–25.2) 13.9 (9.2–22.0)
Negative mood, mean (SD) 16.9 (6.5) 12.6 (7.4)
Morphine, n (%) 45 (77.6) 66 (68.8)
β-Blocker, n (%) 52 (89.7) 84 (87.5)
Antidepressant, n (%) 3 (5.2) 8 (8.3)
Clinical PTSD, n (%) 12 (20.7) 6 (6.3)
CAPS scores, median (IQR)
Total symptom severity 9.6 (4.0–22.0) 7.0 (2.2–12.0)
Reexperiencing symptoms 2.0 (0–6.1) 0 (0–3.0)
Avoidance/numbing symptoms 2.0 (0–6.0) 1.9 (0–3.0)
Hyperarousal symptoms 5.1 (2.0–8.0) 4.0 (2.0–7.0)
The category “Clinical PTSD” includes 1 patient with full PTSD and 17 patients with subsyndromal PTSD. ASD indicates acute stress disorder; CAPS, 
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identified risk factors for cardiac disease–induced 
PTSS.13 The magnitude of this association was clini-
cally significant. In a complementary analysis, we 
found an almost 4-fold increased relative risk of clini-
cal PTSD (full and subsyndromal PTSD combined) in 
patients with benzodiazepine exposure during MI. To 
the extent that CIs were wide and the number of 18 pa-
tients with a diagnosis of clinical PTSD allowed statisti-
cal adjustment for few variables only, this result must 
be interpreted carefully. Nonetheless, the prevalence 
of 11.7% of clinical PTSD in our sample corresponds 
well to the prevalence of 12% (95% CI, 9%–16%) for 
clinically significant ACS-induced PTSS in a previous 
meta-analysis.14 Therefore, the distribution of CAPS 
scores permitted us to find clinically significant effects 
of benzodiazepine use on ACS-induced PTSS, not 
only along a continuum of PTSS severity, but also with 
clinical relevance. Furthermore, for the development of 
ACS-induced PTSS, the effects of benzodiazepines 
could be at least as important as those of known risk 
factors. Younger age and several psychological varia-
bles correlated significantly with the CAPS total sever-
ity score, but benzodiazepine use emerged as the only 
significant predictor besides ASD symptoms in the fully 
adjusted model.
Our observation that administration of a benzodiaz-
epine during ACS is associated with increased PTSS 
is consistent with meta-analytic data from other study 
populations suggesting that benzodiazepines may sig-
nificantly increase the risk of developing PTSD when 
used after recent trauma.16,17 For instance, in one 
study, adults on mechanical ventilation and sedated 
with midazolam showed clinically significant PTSS 
2  months later.37 In another study, the total dose of 
lorazepam that mechanically ventilated patients re-
ceived during the intensive care unit stay was asso-
ciated with PTSS severity 6 months after discharge.38 
On the basis of clinical and experimental studies, 
benzodiazepines could interfere with relearning in the 
recovery from trauma, increasing patients’ vulnerabil-
ity to react with posttraumatic behaviors at times of 
stress and trauma-related cues.17 Inhibited adaptation 
to trauma-related memories39 could explain our ob-
servation of a significant and independent association 
of benzodiazepine use during ACS with reexperienc-
ing symptoms, but not with avoidance/numbing and 
hyperarousal symptoms. We could not confirm earlier 
assumptions that the association of benzodiazepine 
use with PTSS could simply reflect the fact that pa-
tients with increased peritraumatic anxiety16 or ASD38 
are more likely to receive benzodiazepines, as we 
controlled in our analyses for fear of dying and ASD 
symptoms. However, there might be other reasons for 
confounding by indication (ie, the types of patients who 
clinicians believe could benefit from benzodiazepines 
could be exactly those patients who are more likely to 
develop PTSS after ACS, regardless of exposure to a 
benzodiazepine).
Our findings on benzodiazepine use as a potential 
risk factor for ACS-induced PTSS should not discount 
the short-term antianxiety and pain-alleviating effects 
of benzodiazepines. In addition, benzodiazepines may 
have beneficial cardiovascular effects, directly or indi-
rectly, via anxiety reduction; these include vasodilation, 
anti-ischemic and antiarrhythmic properties, platelet 
inhibition, and lowering of catecholamine levels.10 A 
potential alternative to benzodiazepine treatment is re-
assurance of anxious patients admitted with ACS and 
their significant others.6 Unfortunately, this recommen-
dation is often not sufficiently implemented in every-
day clinical practice because of time constraints and 
lack of awareness. Moreover, in a previous study, non-
pharmacological management of anxiety by clinicians 
was not associated with a reduction in anxiety levels 
in patients admitted with ACS, whereas pharmaco-
logical management showed an effect.3 Still, clinicians 
should be aware that ACS-induced PTSS have been 
associated with an increased risk of recurrent cardiac 
events and all-cause mortality.14 Therefore, in patients 
who are candidates for benzodiazepines, the search 
for effective and early behavioral in-hospital interven-
tions to prevent ACS-induced PTSS could particularly 
be justified.40 Targeted means, such as avoiding emer-
gency department crowding,41 could also counteract 
potentially adverse effects of benzodiazepine use on 
the development of ACS-induced PTSS.
We further found that, in contrast to benzodiaze-
pine exposure during ACS, exposure to morphine and 
β-blockers and current use of antidepressants was 
not significantly associated with the development of 
PTSS. This is consistent with the available evidence 
from randomized controlled trials on early pharma-
cotherapy in survivors of noncardiac trauma.22,23,42 
However, such studies are rare, precluding meta-anal-
ysis on effects of morphine,42 which reduced PTSD 
incidence in civilian and military patients,18,19 but may 
delay onset of action of oral antiplatelet agents in pa-
tients with ACS.43 In addition, only propranolol was 
tested,23 a lipophilic and nonselective β-blocker, able 
to cross the blood-brain barrier and to block traumatic 
memory consolidation,44 but not administered during 
ACS. Interestingly, metoprolol, which is also lipophilic 
but a selective β1-adrenoreceptor antagonist, was 
previously suggested to have fear-reducing properties 
after trauma.45 In a previous study, patients exposed to 
β-blockers during emergency department evaluation 
for ACS had less severe PTSS at 1 month, although 
not the subgroup with confirmed ACS, and, unfortu-
nately, the types of used β-blockers were unknown.24 
Previous trials with escitalopram were not prevention, 
but early treatment, trials,46,47 and our patients were 
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vulnerable health of this small subgroup. Specifically, 
current use of antidepressants was associated with a 
history of lifetime depression, poorer self-rated health, 
and negative mood. The rate of almost 30% of preex-
isting depression in our study participants is consistent 
with other cardiovascular literature.48 The low number 
of patients with current use of antidepressants, and 
the high number exposed to morphine and metoprolol 
during ACS as well, made it difficult to find a significant 
group difference for the development of PTSS. Clearly, 
we would need randomized controlled trials to demon-
strate potentially preventive effects of early pharmaco-
therapy on the development of ACS-induced PTSS if 
cardiovascular adverse effects of drug candidates will 
not prohibit this.
Our study yielded further results with potential 
clinical relevance. In accordance with guidelines for 
the pharmacological management of patients with 
STEMI,6 we observed more frequent morphine and 
β-blocker use in STEMI than non–ST-segment–ele-
vation MI, and increased fear of dying in the 38% of 
patients who received a benzodiazepine. Chest pain 
can augment anxiety,10 a possible explanation for 
why fear of dying was associated with morphine use 
in our patients. In contrast, pain intensity was not as-
sociated with any drug, but this could be a result of 
our study design. Patients were eligible to participate 
when they had increased pain during MI, for which the 
vast majority received morphine treatment. This could 
have masked an association between pain scores and 
morphine use. The same could apply to metoprolol, 
previously shown to reduce pain,11 which was adminis-
tered in about 90% of our patients. The variance in fear 
of dying scores was wider, which may have helped to 
reveal significant associations with morphine and ben-
zodiazepine use. These interpretations must consider 
that fear of dying and pain, but also negative mood, 
were assessed several hours after drug administration, 
precluding causal inferences. As negative mood was 
significantly elevated in patients who had received a 
benzodiazepine, the benzodiazepine could have in-
duced negative mood, but the latter could also have 
augmented self-reports on fear of dying in patients’ 
retrospect.
The assessment of PTSS with a clinical interview 
and of a range of potentially important confounding 
variables were strengths of our study, which also had 
its limitations. The findings are based on a secondary 
analysis of data collected from patients with elevated 
levels of pain and fear of dying who participated in a 
behavioral intervention trial. The association between 
benzodiazepine use and PTSS is purely observational, 
was at the lower end of a clinically important effect size, 
and does not prove causality. Particularly, it is possible 
that the same patient characteristics that lead to PTSS 
lead to prescribing a benzodiazepine in the setting of 
an acute MI. Precise information on the dosage and 
time of administration of drugs was not available. The 
sample size precluded inclusion of further covariates in 
statistical models, including health behaviors, so resid-
ual confounding remains a possibility. Our results may 
not be transferable to populations of patients with ACS 
who have less peritraumatic distress but greater diver-
sity in terms of sociodemographic characteristics and 
medical comorbidity. In particular, the low proportion of 
female patients did not allow a stratified analysis by sex. 
The null findings on hyperarousal symptoms must be 
interpreted with caution because of the poor reliability of 
the scale, and whether results would hold with the new 
Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) criteria for PTSD is unclear.
Taken together, we found that benzodiazepine exposure 
during ACS was associated with increased MI-induced 
PTSS severity after 3 months. No such effects were ob-
served for exposure to morphine, exposure to β-blockers, 
and current use of antidepressants during ACS.
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Table S1. Univariable and multivariable binary logistic regression analyses for the risk of clinical PTSD 3 months after MI with drug 
use at hospital admission. 
Variables entered OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Model 1 
Benzodiazepine use 3.89 (1.37, 11.04) .011 
Morphine use 1.02 (0.34, 3.09) .969 
Antidepressant use 3.39 (0.79, 14.43) .099 
Model 2 
Benzodiazepine use 3.75 (1.31, 10.77) .014 
Morphine use 1.03 (0.34, 3.13) .956 
Antidepressant use 3.51 (0.82, 15.10) .092 
ASD symptoms 1.11 (0.75, 1.64) 1.19 (0.81, 1.74) .387 1.20 (0.82, 1.77) .354 
Model 3 
Benzodiazepine use 4.31 (1.46, 12.74) .008 
Morphine use 1.03 (0.32, 3.37) .906 
Antidepressant use 4.48 (0.93, 21.66) .062 
ASD, acute stress disorder; PTSD, posttraumatic stress disorder. ASD scores were square-root transformed. Model 1: univariable associations of each drug 
with clinical PTSD. Model 2: each drug entered with ASD symptoms in one block. Model 3: all three drugs entered in one block. 
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